Merck KGaA's M Ventures Moving On Up With €600m Boost
Significant Cash Injection For Amsterdam-Based Fund
The new capital will allow the VC arm to create and finance "a new and larger portfolio of innovative companies that align with the future strategies" of Merck's businesses.
You may also be interested in...
Merck will develop Chord’s lead drug candidate, an oral version of cladribine, for the treatment of neuromyelitis optica spectrum disorders and generalized myasthenia gravis.
The Finnish company’s endometriosis candidate could offer a better safety profile and be the first drug to address disease progression, Organon claims. Q3 revenues declined slightly due to pandemic, generic competition.
With the number of deals being inked in biopharma continuing apace, the UK firm spoke to Scrip about how to negotiate the line between what big pharma wants and what a biotech is likely to get.